AstraZenecas antibody combination for the prevention of Covid-19 retains neutralization activity against the SARS-CoV-2 variant, according to new data from two UK and US studies. A new study suggests that a new batch of antibodies could be used to prevent the disease.
Source: businesswire.comPublished on 2021-12-23
Related news
- EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
- Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC : AZD7442 PhIII trial positive in COVID outpatients
- AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial
- AstraZeneca plc ( via Public ) / AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial
- New Analyses of Two AZD7442 COVID - 19 Phase III Trials in High - Risk Populations Confirm Robust Efficacy and Long - Term Prevention
- Evusheld long - acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
- AstraZeneca to supply the US government with an additional one million doses of EVUSHELD long - acting antibody combination for the prevention of COVID - 19
- Continued attendance in a PrEP program despite low adherence and non - protective drug levels among adolescent girls and young women in Kenya : Results from a prospective cohort study
- tools , Schema - Root news